PDF下载 ( 1222 KB)
The effect of Telbivudine on virus serology and liver biopsy in HBV carriers
-
摘要: 目的观察HBV携带者经替比夫定治疗后病毒血清学和肝脏病理学的改变情况。方法将42例HBV携带者分成两组,观察组单用替比夫定100 mg/d口服,疗程一年以上,对照组单用苦参素胶囊口服,疗程6个月。观察两组治疗前及治疗后6个月肝脏病理组织学及HBVM、HBVDNA、肝纤维化指标的改变情况。结果治疗6个月后,观察组肝组织改善程度明显优于对照组(P<0.05),观察组肝组织炎症活动指数由治疗前的(7.8±3.8)分下降至治疗后的(4.5±4.2)分(t=7.358,P<0.01),HBVM、HBVDNA、血清纤维化指标与对照组比较也显著改善(P<0.01或<0.05)。结论替比夫定对HBV携带者近期疗效显著,临床上肝功能正常的HBV携带者可进行规范的抗病毒治疗。Abstract: Objective To observe the changes on virus serology and liver biopsy among HBV carriers treated with Telbivu-dine.Methods 42 HBV carriers were divided randomly into treatment group and control group.Telbivudine 100 mg/d was given orally for the treatment group for more than one year.Oxymatrine capsule was given orally for the control group for six months.Liver biopsy and HBVM, HBVDNA and liver fibrosis indexes were tested during the treatment.Results After six months of treatment the improvement of liver biopsy and HBVM, HBVDNA, and liver fibrosis indexes improved significant-ly in the treatment group than the control group (P < 0.05) , and the index of hepatic inflammation activity in the treatment group decreased from 7.8 ± 3.8 to 4.5 ± 4.2 (t = 7.358, P < 0.01) .Conclusion Telbivudine therapy has a significant short-term curative effect on HBV carriers.
-
Key words:
- hepatitis B /
- carrier state /
- hepatitis B antibodies /
- hepatitis B antigens /
- Telbivudine
-
[1]Hann HW.Active antiviral therapy for chronic hepatitis B and hepa-tocellular carcinoma[J].Minerva Gastroenterol Dietol, 2008, 54 (1) ∶19-30. [2]Yamamoto T, Kondo S, Sugawara A, et al.Case of fulminant hepat-ic failure in an elderly asymptomatic HBV carrier without proximatecause[J].Nippon Shokakibyo Gakkai Zasshi, 2008, 105 (12) ∶1781-1786. [3]Lok AS.HBV treatment stragegie should based on publisheddata[J].AGA perspectives, 2006, 2 (1) ∶4-12. [4]中华医学会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2005, 13 (12) ∶881-891. [5]Pan XC, Yang F, Chen M, et al.The effect of telbivudine on pe-ripheral blood CD4+CD25+regulatory T cells and its significancein patients with chronic hepatitis B[J].Zhonghua Gan Zang Bing ZaZhi, 2008, 16 (12) ∶885-888. [6]Chu CM, Liaw YF.Hepatitis B virus-related cirrhosis:natural his-tory and treatment[J].Semin Liver Dis, 2006, 26 (2) ∶142-152. [7]Hui CK, Leung N, Shek WH, et al.Changes in liver histology as a“surrogate”end point of antiviral therapy for chronic HBV can pre-dict progression to liver complications[J].J Clin Gastroenterol, 2008, 42 (5) ∶533-538. [8]Hoofnagle JH, Doo E, Ling TJ, et al.Management of hepatitis B:summary of a clinical reseach workshop[J].Hepatology, 2007, 45 (4) ∶1056-1075. -
本文二维码
计量
- 文章访问数: 4118
- HTML全文浏览量: 16
- PDF下载量: 796
- 被引次数: 0
下载:
